OpenEye Scientific is now part of Cadence

OpenEye Platform Powers $68M Viral Pandemic Treatment Project

OpenEye Platform Powers $68M Viral Pandemic Treatment Project

Cadence Molecular Sciences (OpenEye)—a business unit of Cadence (Nasdaq: CDNS)—has agreed to provide OpenEye’s molecular design software to power the open-science AI-driven Structure-enabled Antiviral Platform (ASAP) Discovery Consortium in support of an innovative effort to rapidly develop antivirals to prevent future pandemics.


The $68M National Institutes of Health Grant was awarded to Chodera Lab to develop their AI-driven Structure-enabled Antiviral Platform (ASAP). ASAP is designed to build on the successes of the COVID Moonshot, a global, open-science collaboration that began in March 2020 and rapidly identified potent antivirals targeting the main protease of the SARS-CoV-2 virus.

Read the full news release here.

For media inquiries, please contact